RCKT Rocket Pharmaceuticals, Inc.

NASDAQ
$2.60

Rocket Pharmaceuticals, Inc. (RCKT) is expected to report earnings on November 5, 2026, after the market close. The consensus earnings estimate is a loss of $0.39 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -29.1% since its last earnings release on August 10, 2026.

Rocket Pharmaceuticals Missed Consensus Estimates
Monday, August 10, 2026 · 4:00 PM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 5
Thursday · 4:00 PM ET
Earnings Whisper
-
vs ($0.39)
Rev est $1.5M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $3.52

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Rocket Pharmaceuticals, Inc.

Rocket Pharmaceuticals, Inc. is an emerging, clinical-stage biotechnology company. It focused on developing first-in-class gene therapy treatment options for rare, undertreated diseases. Rocket Pharmaceuticals Inc., formerly known as Inotek Pharmaceuticals Corporation, is based in LEXINGTON, United States.

Sector

Healthcare

Industry

Biotechnology

Held By 4 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.